Treatment of human immunodeficiency virus (HIV)-associated nephropathy

Seminars in Nephrology

Volumn 18, Issue 4, 1998, Pages 446-458

  Kimmel, Paul L ^a   Bosch, Juan P ^a   Vassalotti, Joseph A ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; LAMIVUDINE; PREDNISONE; ZIDOVUDINE;

CORTICOSTEROID THERAPY; CREATININE CLEARANCE; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG CHOICE; DRUG INDICATION; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION;

AIDS-ASSOCIATED NEPHROPATHY; ANTIVIRAL AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 0031853607     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Rao TKS, Filippone EJ, Nicastri AD, et al: Associated focal and segmentai glomerulosclerosis in the acquired immunodeficiency syndrome. N EngI J Med 310:669-673, 1984
2. Pardo V, Aldana M, Colton RM, et al: Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 101:429-434, 1984
3. Strauss J, Abitbol C, Zilleruelo G, et al: Renal disease in children with the acquired immunodeficiency syndrome. N Engl J Med 321:625-630, 1989
4. Rao KS, Friedman EA, Nicastri AD: The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 316:1062-1068, 1987
5. Cantor ES, Kimmel PL, Bosch JP: Effect of race on the expression of AIDS-associated nephropathy. Arch Intern Med 151:125-128, 1991
6. Langs C, Gallo OR, Schacht RG, et al: Rapid renal failure in AIDS focal Glomerulosclerosis. Arch Int Med 150:287-292, 1990
7. Bourgoignie JJ: Renal complications of human immunodeficiency virus type 1. Kidney Int 37:1571-1584, 1990
8. Glassock RJ (moderator): Human immunodeficiency virus and the kidney. Ann Intern Med 112:35-49, 1990
9. Guerra IL, Abraham AA, Kimmel PL, et al: Nephrotic syndrome associated with chronic persistent Hepatitis B in an HIV antibody positive patient. Am J Kidney Dis 10:385-388, 1987
10. Kimmel PL, Berns JS, Stein JH, (Eds): Renal and Urologie Aspects of HIV Infection. New York, NY, Churchill Livingstone, 1995
11. Kimmel PL: Renal diseases in HIV infected patients: Pathogenesis, diagnosis and treatment. AIDS Patient Care STDs 10:342-348, 1996
12. Vassalotti JA, Kimmel PL: HIV-associated nephropathies. Mediguide Nephrol 4:1-7, 1997
13. Kimmel PL: Treatment of HIV nephropathies, in Glassock RJ (ed): Current Therapy in Nephrology and Hypertension. St. Louis, MO, Mosby, 1997 (in press)
14. Kimmel PL: HIV-associated Renal Diseases: Diagnosis and Therapy, in Dolin R, Masur H, Saag M (eds): AIDS Therapy. New York, NY, Churchill Livingstone, 1997 (in press)
15. D'Agati V, Appel GB: HIV infection and the kidney. J Am Soc Nephrol 8:138-152, 1997
16. Ingulli E, Tejani A, Fikrig S, et al: Nephrotic syndrome associated with acquired immunodeficiency in children. J Pediatr 119:710-716, 1991
17. Appel RG, Neill J: A steroid-responsive nephrotic syndrome in a patient with human immunodeficiency virus infection. Ann Intern Med 113:892-895, 1990
18. Briggs WA, Tanawattanacharoen S, Choi MJ, et al: Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephroapthy. Am J Kidney Dis 28:618-621, 1996
19. Watterson MK, Detwiler RK, Bolin P Jr: Clinical response to prolonged corticosteroids in a patient with human immunodeficiency virus-associated nephropathy. Am J Kidney Dis 29:624-646, 1997
20. Smith MC, Pawar R, Carey JT, et al: Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy. Am J Med 97:145-151, 1994
21. Smith MC, Austen JL, Carey JT, et al: Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 101:41-48, 1996
22. Strauss J, Zilleruelo G, Abitbol C, et al: Human immunodeficiency virus nephropathy. Pediatr Nephrol 7:220-225, 1993
23. Bodi I, Abraham AA, Kimmel PL: Macrophages in HIV-associated kidney diseases. Am J Kidney Dis 24:762-767, 1994
24. Kimmel PL, Mishkin GJ, Umana WO: Captopril and renal survival in patients with human immunodeficiency virus nephropathy. Am J Kidney Dis 28:202-208, 1996
25. Burns GC, Paul SK, Toth I, et al: Effect of angiotensinconverting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 8:1140-1146, 1997
26. Koibuchi Y, Lee WS, Gibbons GH, Pratt RE: Role of transforming growth factor-β in the cellular growth response to angiotensin II. Hypertension 21:1046-1050, 1993
27. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med 331:1285-1292, 1994
28. Wolf G, Mueller E, Stahl AK, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 92:1366-1372, 1992
29. Border WA, Ruoslahti E: TGF-β in disease: The dark side of tissue repair. J Clin Invest 90:1-7, 1992
30. Sharma K, Ziyadeh F: The transforming growth factor-β system and the kidney. Semin Nephrol 13:116-128, 1993
31. Kekow J, Wachsman W, McCutchan A, et al: Transforming growth factor-β and noncytopathic mechanisms of immunodeficiency in HIV infection. Proc Natl Acad Sei 87:8321-8325, 1990
32. Allen JB, Wong HL, Guyre PM, et al: Association of circulating receptor FCYRIII+ monocytes in AIDS patients with elevated TGF-β levels. J Clin Invest 87:1773-1779, 1991
33. Bodi I, Kimmel PL, Abraham AA, et al: Renal TGF-β in HIV-associated kidney diseases. Kidney Int 51:1568-1577, 1997
34. Shukla RR, Kumar A, Kimmel PL: Transforming growth factor-β increases the expression of HIV-1 gene in transfected human mesangial cells. Kidney Int 44:1022-1029, 1993
35. Shukla RR, Kimmel PL, Kumar A: Molecular biology of HIV-1 and kidney disease. Kimmel PL, Berns JS, Stein JH (eds): Renal and Urologie Aspects of HIV Infection. New York, NY, Churchill Livingstone, 1995, pp 77-110
36. Rappaport J, Kopp JB, Klotman PE: Host virus interactions and the molecular regulation of HIV-1: Role in the pathogenesis of HIV-associated nephropathy. Kidney Int 46:16-27, 1994
37. Humphreys MH: Human immunodeficiency virus-associated glomerulosclerosis. Kidney Int 48:311-320, 1995
38. Sharma SK, Evans DB, Hui JO, Heinrikson RL: Could angiotensin I be produced from a renin substrate by the HIV-1 protease? Anal Biochem 198:363-367, 1991
39. Ouellete DR, Kelly JW, Anders GT: Serum angiotensin converting enzyme level is elevated in patients with HIV infection. Arch Intern Med 152:321-324, 1992
40. Friedland J, Setton C, Silverstein E: Induction of angiotensin converting enzyme in human moncytes in culture. Biochem Biophys Res Comm 83:843-849, 1978
41. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F: Angiotensin converting enzyme in human circulating mononuclear cells: Genetic polymorphism of expression in T lymphocytes. Biochem J 290:33-40, 1993
42. Kozlowski S, Corr M, Takeshita T, et al: Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp 160 peptide for presentation by major histocompatibility complex class I molecules. J Exp Med 175:1417-1422, 1992
43. Eisenlohr LC, Bacik I, Bennink JR, et al: Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T-lymphocytes. Cell 71:963-972, 1992
44. Choe H, Farzan M, Sun Y, et al: The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148, 1996
45. Doranz BJ, Rucker J, Yi Y, et al: A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion factors. Cell 85:1149-1158, 1996
46. Bates P: Chemokine receptors and HIV-1: An attractive pair? Cell 86:1-3, 1996
47. Liu R, Paxton WA, Choe S, et al: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiplyexposed individuals to HIV-1 infection. Cell 86:367-377, 1996
48. Samson M, et al: Resistance to HIV-1 infection in Caucasians bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725, 1996
49. Kimmel PL, Bodi I, Abraham A, Phillips TM: Increased renal tissue cytokines in human HIV nephropathy. J Am Soc Nephrol 4:279, 1993 (abstr)
50. Wenzel UO, Abboud HA: Chemokines and renal disease. Am J Kidney Dis 26:982-994, 1995
51. Schlondorff D, Nelson PJ, Luckow B, et al: Chemokines and renal disease. Kidney Int 51:610-621, 1997
52. Stahl RAK: Potential role of chemokines in human renal disease. Am J Kidney Dis 30:441-443, 1997
53. Winston JA, Klotman PE: Are we missing an epidemic of HIV-associated nephropathy? J Am Soc Nephrol 7:1, 1996
54. Stevens A, Little J, Kerr S, et al: HIV testing in patients with end stage renal disease. Br Med J 300:447-449, 1990
55. Neugarten JS, Kimmel PL: HIV and dialysis: Occupational risk and medical legal implications, in Kimmel PL, Berns JS, Stein JH (eds): Renal and Urologie Aspects of HIV infection. New York, NY, Churchill Livingstone, 1995, pp 279-306
56. Centers for Disease Control: HIV Transmission in a Dialysis Center-Colombia, 1991-1993. JAMA 274:372-373, 1995
57. Vijayvargiya R, Bosch J: Dialysis and transplantation in patients with HIV infection, in Kimmel PL, Berns JS, Stein JH (eds): Renal and Urologie Aspects of HIV Infection. New York, NY, Churchill Livingstone, 1995, pp 253-277
58. Dyer E: Argentinian doctors accused of spreading AIDS. Br Med J 307:584, 1993
59. Velandia M, Fridkin SK, Cardenas V, et al: Transmission of HIV in a dialysis centre. Lancet 345:1417-1422, 1995
60. Shaldon S: Transmission of HIV in dialysis centers. Lancet 346:451, 1995 (letter)
61. Centers for Disease Control: Recommendations for providing dialysis treatment to patients infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. Ann Intern Med 105:558-559, 1986
62. Ippolito G, Puro V, De Carli G, et al: The risk of occupational human immunodeficiency virus infection in health care workers. Arch Intern Med 153:1451-1458, 1993
63. Royce RA, Sena A, Gates W, et al: Sexual transmission of HIV. N Engl J Med 336:1072-1078, 1997
64. Kimmel PL, VedBrat SS, Pierce PF, et al: Prevalence of human immunodeficiency virus-infected patients with renal disease. Arch Intern Med 155:1578-1584, 1995
65. Feinfeld DA, Kaplan R, Dressier R, et al: Survival of human immunodeficiency virus-I infected patients on maintenance hemodialysis. Clin Nephrol 32:221, 1989
66. Tebben JA, Rigsby MO, Selwyn PA, et al: Outcome of HIV infected patients on continuous ambulatory peritoneal dialysis. Kidney Int 44:191-198, 1993
67. Ortiz C, Meneses R, Jaffe D, et al: Outcome of patients with human immunodeficiency virus on maintenance hemodialysis. Kidney Int 34:248-253, 1988
68. Kimmel PL, Umana WO, Simmens SJ, et al: Continuous ambulatory peritoneal dialysis and survival of HIV infected patients with end-stage renal disease. Kidney Int 44:373-378, 1993
69. Ifudo O, Mayers JD, Matthew JJ, et al: Uremia therapy in patients with end-stage renal disease and human immunodeficiency virus infection: Has the outcome changed in the 1990s? Am J Kidney Dis 29: 549-552, 1997
70. Perinbasekar S, Brod-Miller C, Pal S: Predictors of survival in HIV-infected patients on hemodialysis. Am J Nephrol 16:280-286, 1996
71. Brock JS, Sussman M, Wamsley M, et al: The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery. J Vase Surg 16:904-912, 1992
72. Nannery WM, Stoldt HS, Fares LG: Hemodialysis access operations performed upon patients with human immunodeficiency virus. Surg Gynecol Obstet 173:387-390, 1991
73. Shrivastava D, Rao TKS, Sinert R, et al: The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis 25:904-909, 1995
74. Phair JP, Abels RI, McNeill MV, et al: Recombinant human erythropoietin treatment: Investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Arch Intern Med 153:2669-2675, 1993
75. Henry DH, Jemsek JG, Levin AS, et al: Recombinant human erythropoietin and the treatment of anemia in patients with AIDS or advanced ARC not receiving ZDV. J AIDS 8:847-848, 1992 (letter)
76. Kimmel PL, Lew SQ, Umana WO, et al: Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease. Blood Purif 13:340-346, 1995
77. Heald AE, Hsyu PH, Yuen GJ, et al: Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother 40:1514-1519, 1996
78. Lewis M, Gorban-Brennan NL, Kliger A, et al: Incidence and spectrum of organisms causing peritonitis in HIV positive patients on CAPD. Adv Perit Dial 6:136-138, 1990
79. Dressier R, Peters AT, Lynn RI: Pseudomonal and candidal peritonitis as a complication of continuous ambulatory peritoneal dialysis in human immunodeficiency virus-infected patients. Am J Med 86:787-790, 1989
80. Elsey RM, Carson RW, Dubose TD: Pasturella multocida peritonitis in an HIV-positive patient on continuous cycling peritoneal dialysis. Am J Nephrol 11:61-63, 1991
81. Parsonnet J: Trichosporon beigelii Peritonitis. South Med J 82:1062-1063, 1989
82. Perazella M, Eisen T, Brown E: Peritonitis associated with disseminated mycobacterium avium complex in an acquired immunodeficiency syndrome patient on chronic ambulatory peritoneal dialysis. Am J Kidney Dis 21:319-321, 1993
83. Wasser WG, Boyle MJ, Brandon S, et al: HIV positivity does not predispose peritoneal dialysis patients to peritonitis. J Am Soc Nephrol 2:369, 1991 (abstr)
84. Kieman L, Finkelstein FO, Kliger AS, et al: Outcome of polymicrobial peritonitis in continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 25:461-464, 1995
85. Breyer JA, Harbison MA: Isolation of human immunodeficiency virus from peritoneal dialysate. Am J Kidney Dis 21:23-25, 1993
86. Scheel PJ, Malan M, Watson A, et al: Recovery of human immunodeficiency virus from peritoneal dialysis effluent. J Am Soc Nephrol 5:1926-1929, 1995
87. Farzadegan H, Ford D, Malan M, et al: HIV-1 survival kinetics in peritoneal dialysis effluent. Kidney Int 50:1659-1662, 1996
88. Gallicano KD, Tobe S, Sahai J, et al: Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD). J AIDS 5:242-250, 1992
89. Lang Ph, Niaudet P, Groupe Cooperatif de Transplantation de l'Ile de France: Update and outcome of renal transplant patients with human immunodeficiency virus. Transplant Proc 23:1352-1353, 1991
90. Prompt CA, Reis MM, Grillo FM, et al: Transmission of AIDS virus at renal transplantation. Lancet 2:672, 1985
91. Rubin RH, Jenkins RL, Shaw BW, et al: The acquired immunodeficiency syndrome and transplantation. Transplant 44:1-4, 1987
92. Shaffer D, Pearl RL, Jenkins RL, et al: HTLV-III/ LAV infection in kidney and liver transplantation. Transplant Proc 19:2176-2178, 1987
93. Perez G, Ortiz-Interian C, Bourgoignie JJ, et al: HIV-1 and HTLV-1 infection in renal transplant recipients. J AIDS 3:35-40, 1990
94. Milgrom M, Esquenazi V, Fuller L, et al: Acquired immunodeficiency syndrome in a transplant patient. Transplant Proc 17:75-76, 1985
95. Schwarz A, Offermann G, Keller F, et al: The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation - Data on four cases and review of the literature. Transplant 55:95-103, 1993
96. Carbone LG, Cohen DJ, Hardy MA, et al: Determination of acquired immunodeficiency syndrome (AIDS) after renal transplantation. Am J Kidney Dis 11:387-392, 1988
97. Bowen PA, Lobel SA, Caruana RJ, et al: Transmission of human immunodeficiency virus (HIV) by transplantation: Clinical aspects and time course analysis of viral antigenemia and antibody production. Ann Intern Med 108:46-48, 1988
98. Hirano A, Yasukawa T, Ohkawa T, et al: Analysis of lymphocyte subsets in a renal allograft recipient infected with human immunodeficiency virus. Br J Urol 74:283-287, 1994
99. Oliveira DBG, Winearls CG, Cohen J, et al: Severe immunosuppression in a renal transplant recipient with HTLV-III antibodies. Transplant 1:260-262, 1986
100. Erice A, Rhame FS, Dunn DL, et al: Neutropenia in an HIV-1-infected renal transplant recipient treated with zidovudine. JAMA 259:3407-3408, 1988 (letter)
101. Rubin RH, Wolfson JS, Cosimi AB, et al: Infection in the renal transplant recipient. Am J Med 70:405-411, 1981
102. Frem GJ, Rennke HG, Sayegh MH: Late renal allograft failure secondary to thrombotic microangiopathy-human immunodeficiency virus nephropathy. J Am Soc Nephrol 4:1643-1648, 1994
103. Shelling JR, Baum KF, Teitelbaum I: Didanosine administration in a human immunodeficiency virus-positive renal transplant patient. Am J Kidney Dis 22:60-63, 1993